Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
LifeMD, Inc. (NASDAQ: LFMD) has priced an underwritten public offering of 3,333,334 shares of common stock at $6.00 per share, aiming for gross proceeds of about $20 million. The offering includes a 30-day option for underwriters to purchase an additional 500,000 shares. The funds will be utilized to reduce debt and support working capital, including expenses for acquiring new patients and capital expenditures. The offering is expected to close on October 4, 2021, following customary conditions.
LifeMD, Inc. (NASDAQ: LFMD) has initiated an underwritten public offering of its common stock, with expectations to grant underwriters a 30-day option for additional shares. The company plans to use the net proceeds to reduce its debt and fund working capital, particularly for customer acquisition and capital expenditures. B. Riley Securities, Inc. is the lead manager for this offering, which is being conducted under an effective shelf registration statement. The press release emphasizes that this offering does not constitute an offer to sell securities in jurisdictions where it would be unlawful.
LifeMD, Inc. (NASDAQ: LFMD) has announced a public offering of 1,400,000 shares of Series A Cumulative Perpetual Preferred Stock, totaling a liquidation preference of $35 million. The offering includes a 30-day option for underwriters to purchase an additional 210,000 shares. Proceeds will be allocated to fund a segregated dividend account, repay a portion of debt, and for working capital including customer acquisition and capital expenditures. Book-running managers include B. Riley Securities and others, with the offering made under an effective shelf registration statement.
LifeMD, Inc. (NASDAQ: LFMD) has announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, at 12:40 PM ET. The telehealth company offers cash pay virtual medical treatments, prescription medications, and over-the-counter products to patients nationwide. Management will be available for virtual one-on-one meetings, with details accessible via a corporate contact link. LifeMD continues to expand its telemedicine platform to provide accessible healthcare solutions to patients across all 50 states.
LifeMD appoints Naveen Bhatia to its board of directors, enhancing its leadership as the company evolves in the telehealth sector. Bhatia, a seasoned investor with experience at Blackstone and various boards, brings significant financial and management expertise. His addition is expected to provide valuable insights and executional skills to LifeMD's growth strategy. The company aims to transform healthcare access for Americans through its telehealth platform, which focuses on delivering affordable, cash-pay virtual medical care nationwide.
LifeMD, a fast-growing telehealth company, announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The event will feature virtual presentations and one-on-one investor meetings. LifeMD specializes in providing cash pay virtual medical treatments, prescription medications, and over-the-counter products to patients nationwide. The company's platform allows easy access to licensed medical professionals, enhancing patient convenience.
LifeMD, Inc. (NASDAQ: LFMD) announced a strategic partnership with Prescryptive Health, enhancing its telehealth capabilities. This collaboration will provide LifeMD with access to a nationwide pharmacy network and a digital pharmacy fulfillment platform. Key benefits include improved delivery times for prescriptions, expanded medication offerings, and the introduction of a prescription drug discount program. This initiative aims to strengthen LifeMD's position in the $500 billion U.S. prescription pharmacy market and enhance patient access to healthcare services.
LifeMD reported record revenue of $22.3 million for Q2 2021, marking a 145% increase year-over-year. 93% of revenue came from subscriptions, up from 56% last year. The total telehealth order volume grew by 155%, reaching 199,764 orders. Customer Acquisition Costs (CAC) decreased by 8% sequentially, while new patient acquisitions improved by 11%. Despite a net loss of $16.8 million, LifeMD reiterated its 2021 revenue guidance of $90 million to $100 million, signaling strong market demand and strategic growth initiatives.
LifeMD (NASDAQ: LFMD) announced a partnership with Particle Health to enhance personalized medical care through improved access to patient health records. With access to a database covering over 90% of the U.S. population, licensed providers can leverage comprehensive health data, paving the way for better healthcare outcomes. This strategic alliance aims to simplify healthcare delivery and strengthen patient-provider relationships, ultimately driving the launch of LifeMD's primary care platform.
LifeMD, Inc. (NASDAQ: LFMD) announced a conference call to discuss its second quarter fiscal 2021 financial results on August 12, 2021, at 4:30 p.m. ET. The results will be released prior to the call, and management will host the discussion followed by a Q&A session. LifeMD offers direct-to-patient telehealth services and products nationwide. The call can be accessed via toll-free and international dial-in numbers or streamed online. Interested parties should review the company's SEC filings for risk factors and historical financial data.
FAQ
What is the current stock price of Lifemd (LFMD)?
What is the market cap of Lifemd (LFMD)?
